School of Medicine
Showing 1-10 of 45 Results
-
Christine Anastasiou, MD, MAS
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
BioDr. Anastasiou is a board-certified, fellowship-trained rheumatologist with the Stanford Health Care Immunology and Rheumatology Clinic. She is also a clinical assistant professor in the Department of Medicine, Division of Immunology and Rheumatology at Stanford University School of Medicine.
Dr. Anastasiou specializes in diagnosing and treating patients with rheumatic diseases. She has a special interest in ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, and idiopathic inflammatory myopathies.
Her scholarly work includes epidemiologic studies and clinical trials focused on improving safety and health outcomes for people with chronic rheumatic diseases. Dr. Anastasiou has served as an investigator and collaborator for clinical trials of new therapies to treat rheumatic disease. She is actively involved in medical education through developing and leading patient, medical student, resident, and fellow educational programs.
Dr. Anastasiou is a member of the American College of Rheumatology (ACR). She has published her research in peer-reviewed journals, including Arthritis Care & Research and Lupus Science & Medicine. She has delivered lectures and presentations across the country and abroad on various topics related to rheumatology. -
Matthew C. Baker, MD MS
Assistant Professor of Medicine (Immunology and Rheumatology)
BioDr. Baker is the Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University and an internationally recognized expert in IgG4-related disease, as well as the Co-Founder and Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. He received his bachelor's degree from Pomona College, his medical degree from Harvard Medical School, and his master's degree in Epidemiology and Clinical Research from Stanford University. He completed his Internal Medicine residency at the Massachusetts General Hospital and his Rheumatology fellowship at Stanford University. Dr. Baker's clinical research program is focused on clinical trials, epidemiological studies, and bench-to-bedside translational research. He has designed and led investigator-initiated and industry sponsored clinical trials in IgG4-related disease, sarcoidosis, Sjogren's disease, and rheumatoid arthritis. His epidemiological work aims to better understand disease mechanisms and identify novel drug targets, with a particular interest in repurposing existing drugs for the treatment of osteoarthritis.
-
Yashaar Chaichian, MD
Clinical Associate Professor, Medicine - Immunology & Rheumatology
Current Research and Scholarly InterestsSystemic lupus erythematosus
CTD-associated interstitial lung disease -
Alvina Dor-Yan Chu
Adjunct Clinical Assistant Professor, Medicine - Immunology & Rheumatology
BioAlvina Chu, MD, is an adjunct clinical faculty member within the Division of Immunology and Rheumatology. She has practiced rheumatology for more than 10 years, specializing in treatment of a wide range of chronic inflammatory conditions including rheumatoid arthritis, lupus, vasculitis, and gout.
She holds a longstanding scientific interest in immunology, especially the role of B-cell signaling mechanisms in lupus and other autoimmune diseases.
In addition to taking care of patients in clinic and in the hospital, Dr. Chu enjoys teaching and mentoring fellows, residents, and medical students. -
Lorinda Chung
Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy research interests focus on all aspects of systemic sclerosis. I am currently involved in clinical, translational, and epidemiologic research in these areas, and dedicate a substantial portion of my research time to investigator-initiated and multi-center clinical trials of novel therapeutics for the treatment of systemic sclerosis.
-
Kimberly DeQuattro, MD, MM
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
BioDr. Kimberly DeQuattro is a board-certified, rheumatologist at Stanford Health Care and a clinical assistant professor in the Department of Medicine, Division of Immunology and Rheumatology at Stanford University School of Medicine.
Dr. DeQuattro specializes in the care of people with systemic lupus erythematosus as well as adolescents and young adults with childhood onset rheumatologic conditions. Her clinical focus includes systemic lupus erythematosus, lupus nephritis, juvenile idiopathicarthritis, and the transition from pediatric to adult rheumatology care.
She has special expertise in treating complex lupus, including kidney disease (lupus nephritis) and reproductive health concerns linked to autoimmune conditions. Her team-based, trauma-informed approach considers not only medical needs but also social factors that affect health, making sure care is fair and comprehensive.
Her research looks at how lupus affects people differently, especially in underserved groups, and how stress and trauma can impact the course of the disease. She also studies ways to help young patients move smoothly from pediatric to adult care. Dr. DeQuattro has helped lead team-based lupus clinics and support programs that include social workers. She also works on clinical trials testing new treatments, including CAR T-cell therapy, for patients with hard-to-treat lupus.
Dr. DeQuattro’s work has been featured at national meetings including the American College of Rheumatology (ACR) and the Society of General Internal Medicine. She has authored book chapters and collaborated on more than 20 articles in peer-reviewed publications, including Arthritis Care & Research, Lupus Science & Medicine, and Rheumatology. Her work has covered topics such as lupus, lupus nephritis, pediatric to adult rheumatology, and health equity. In 2024 and 2025, she contributed to the ACR’s updated clinical guidelines for lupus nephritis and lupus. She serves on key ACR working groups.
She is a member of the American College of Rheumatology and the Childhood Arthritis and Rheumatology Research Alliance. -
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
On Leave from 07/01/2025 To 06/30/2026Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
Robert Michael Fairchild
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDr. Fairchild’s research focuses on musculoskeletal and organ-based ultrasound in rheumatic disease, including arthritis, calcinosis, vascular pathology, and interstitial lung disease. He develops ultrasound-based outcome measures and leads projects applying deep learning and explainable AI to imaging. He also performs ultrasound-guided synovial biopsies to support translational and clinical research.
-
Titilola Falasinnu
Assistant Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)
BioI am primarily a lupus researcher and identify as a pain scientist and methodologist in this field. Systemic lupus erythematosus (SLE) disproportionately affects women and racial minorities and is the fifth most common cause of death among 15- to 24-year-old Black and Hispanic women in the U.S., highlighting its significant public health impact. More than half of patients with SLE experience chronic pain, often secondary to SLE itself or overlapping conditions (e.g., migraines, low back pain, fibromyalgia), contributing significantly to disability and impaired quality of life. Chronic pain is not merely a symptom but a disease in its own right—one that deserves the same rigorous study and clinical attention as comorbidities like kidney disease and cardiovascular disease in rheumatology. The enormous global burden of chronic pain underscores the urgent need for a clear, standardized definition of pain as a disease, particularly in autoimmune rheumatic diseases where pain can arise from inflammatory, nociplastic, and biopsychosocial mechanisms. Without recognizing pain as a distinct disease entity, its mechanisms remain poorly understood, and effective treatment strategies remain underdeveloped.
I am a co-Principal Investigator of the Pain Intelligence Lab, where our mission is to advance the study of pain as a disease in rheumatology through two primary objectives. First, we develop and validate computational methods that enable clinicians and researchers to leverage electronic health records, administrative claims, and disease registries to study chronic pain as a distinct disease entity in rheumatology. By applying machine learning, natural language processing, and real-world data analysis, we seek to enhance pain phenotyping, classify distinct pain subtypes, and develop predictive models for treatment response. Second, we use a biopsychosocial framework to examine the predictive power of biomarkers and psychosocial measures in rheumatologic pain. By integrating biological, psychological, and social determinants of pain, we aim to conduct rigorous, patient-oriented research that translates targeted assessments into mechanistically informed, personalized treatment approaches for optimized clinical care. Ultimately, my long term career goal is to bridge the gap between research and clinical practice, ensuring that pain management in autoimmune rheumatic diseases is precise, equitable, and optimized for improved patient outcomes. -
C. Garrison Fathman
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.
